somatostatin + ulinastatin

A combination therapy consisting of somatostatin and ulinastatin used primarily for the treatment of severe acute pancreatitis (SAP). Somatostatin works by preventing autolysis of the pancreas, while ulinastatin is a protease inhibitor that helps reduce inflammation. Together, they create a synergistic effect that enhances treatment outcomes. Clinical studies have shown that this combination is more effective than either drug used alone, particularly in reducing inflammatory responses, improving gastrointestinal function, enhancing immune function, and shortening recovery times in patients with severe pancreatitis.